This may be due to the ability of EGCG to increase alpha secretase activity (the nonamyloidogenic pathway of APP processing) as discovered in a transgenic Alzheimer's disease mouse model [44]. The gene discussed is APP; the disease is early-onset autosomal dominant Alzheimer disease.